Which drug or drug delivery system can change clinical practice for brain tumor therapy?

被引:37
作者
Siegal, Tali [1 ]
机构
[1] Hadassah Hebrew Univ, Gaffin Ctr Neurooncol, Med Ctr, IL-91120 Jerusalem, Israel
关键词
blood-brain barrier; brain drug delivery; brain tumor; brain tumor therapy; clinical practice; CNS; drug development; drug efflux mechanism; CONVECTION-ENHANCED DELIVERY; CENTRAL-NERVOUS-SYSTEM; RECURRENT MALIGNANT GLIOMA; CANCER RESISTANCE PROTEIN; BARRIER DISRUPTION; IN-VIVO; MULTIDRUG-RESISTANCE; FOCUSED ULTRASOUND; P-GLYCOPROTEIN; TARGETED TOXIN;
D O I
10.1093/neuonc/not016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The prognosis and treatment outcome for primary brain tumors have remained unchanged despite advances in anticancer drug discovery and development. In clinical trials, the majority of promising experimental agents for brain tumors have had limited impact on survival or time to recurrence. These disappointing results are partially explained by the inadequacy of effective drug delivery to the CNS. The impediments posed by the various specialized physiological barriers and active efflux mechanisms lead to drug failure because of inability to reach the desired target at a sufficient concentration. This perspective reviews the leading strategies that aim to improve drug delivery to brain tumors and their likelihood to change clinical practice. The English literature was searched for defined search items. Strategies that use systemic delivery and those that use local delivery are critically reviewed. In addition, challenges posed for drug delivery by combined treatment with anti-angiogenic therapy are outlined. To impact clinical practice and to achieve more than just a limited local control, new drugs and delivery systems must adhere to basic clinical expectations. These include, in addition to an antitumor effect, a verified favorable adverse effects profile, easy introduction into clinical practice, feasibility of repeated or continuous administration, and compatibility of the drug or delivery system with any tumor size and brain location.
引用
收藏
页码:656 / 669
页数:14
相关论文
共 151 条
  • [1] Isolation and cultivation of human keratinocytes from skin or plucked hair for the generation of induced pluripotent stem cells
    Aasen, Trond
    Izpisua Belmonte, Juan Carlos
    [J]. NATURE PROTOCOLS, 2010, 5 (02) : 371 - 382
  • [2] Afra D, 2002, LANCET, V359, P1011
  • [3] Function of the Blood-Brain Barrier and Restriction of Drug Delivery to Invasive Glioma Cells: Findings in an Orthotopic Rat Xenograft Model of Glioma
    Agarwal, Sagar
    Manchanda, Pooja
    Vogelbaum, Michael A.
    Ohlfest, John R.
    Elmquist, William F.
    [J]. DRUG METABOLISM AND DISPOSITION, 2013, 41 (01) : 33 - 39
  • [4] Active Efflux of Dasatinib from the Brain Limits Efficacy against Murine Glioblastoma: Broad Implications for the Clinical Use of Molecularly Targeted Agents
    Agarwal, Sagar
    Mittapalli, Rajendar K.
    Zellmer, David M.
    Gallardo, Jose L.
    Donelson, Randy
    Seiler, Charlie
    Decker, Stacy A.
    SantaCruz, Karen S.
    Pokorny, Jenny L.
    Sarkaria, Jann N.
    Elmquist, William F.
    Ohlfest, John R.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2012, 11 (10) : 2183 - 2192
  • [5] Insight into the Cooperation of P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) at the Blood-Brain Barrier: A Case Study Examining Sorafenib Efflux Clearance
    Agarwal, Sagar
    Elmquist, William F.
    [J]. MOLECULAR PHARMACEUTICS, 2012, 9 (03) : 678 - 684
  • [6] Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
    Agarwal, Sagar
    Hartz, Anika M. S.
    Elmquist, William F.
    Bauer, Bjoern
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (26) : 2793 - 2802
  • [7] Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain
    Agarwal, Sagar
    Sane, Ramola
    Oberoi, Rajneet
    Ohlfest, John R.
    Elmquist, William F.
    [J]. EXPERT REVIEWS IN MOLECULAR MEDICINE, 2011, 13 : e17
  • [8] Convection-enhanced delivery of nanocarriers for the treatment of brain tumors
    Allard, Emilie
    Passirani, Catherine
    Benoit, Jean-Pierre
    [J]. BIOMATERIALS, 2009, 30 (12) : 2302 - 2318
  • [9] Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
    Alvarez-Erviti, Lydia
    Seow, Yiqi
    Yin, HaiFang
    Betts, Corinne
    Lakhal, Samira
    Wood, Matthew J. A.
    [J]. NATURE BIOTECHNOLOGY, 2011, 29 (04) : 341 - U179
  • [10] Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience
    Angelov, Lilyana
    Doolittle, Nancy D.
    Kraemer, Dale F.
    Siegal, Tali
    Barnett, Gene H.
    Peereboom, David M.
    Stevens, Glen
    McGregor, John
    Jahnke, Kristoph
    Lacy, Cynthia A.
    Hedrick, Nancy A.
    Shalom, Edna
    Ference, Sandra
    Bell, Susan
    Sorenson, Lisa
    Tyson, Rose Marie
    Haluska, Marianne
    Neuwelt, Edward A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) : 3503 - 3509